Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study.
about
Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004).Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK's Haematological Malignancy Research Network (HMRN).Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma.Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma.
P2860
Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Predictive factors and outcome ...... lymphoma-a "real world" study.
@en
Predictive factors and outcome ...... lymphoma-a "real world" study.
@nl
type
label
Predictive factors and outcome ...... lymphoma-a "real world" study.
@en
Predictive factors and outcome ...... lymphoma-a "real world" study.
@nl
prefLabel
Predictive factors and outcome ...... lymphoma-a "real world" study.
@en
Predictive factors and outcome ...... lymphoma-a "real world" study.
@nl
P2093
P2860
P356
P1476
Predictive factors and outcome ...... lymphoma-a "real world" study.
@en
P2093
Abraham S Kanate
Amanda F Cashen
Chadi Nabhan
Eunhye Oak
Jonathon B Cohen
Kwang W Ahn
Luciano J Costa
Luke Farmer
Mehdi Hamadani
Michael Tallarico
P2860
P356
10.1002/HON.2380
P577
2017-01-08T00:00:00Z